Allergan Plc Acquires RetroSense Therapeutics for $60,000,000

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=265a57a5-75bf-474d-8f14-cb009ca07fff
Date
9/6/2016
Company Name
RetroSense Therapeutics
Mailing Address
330 East Liberty Street LL Ann Arbor, MI 48104 USA
Company Description
Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel gene therapy approach to vision restoration.
Website
http://www.retro-sense.com
Transaction Type
M&A
Transaction Amount
$60,000,000
Transaction Round
Proceeds Purposes
M&A Terms
Under the terms of the transaction, Allergan has paid RetroSense a $60 million upfront payment, and has agreed to potential regulatory and commercialization milestone payments related to its lead development program, RST-001, a novel gene therapy for the potential treatment of Retinitis Pigmentosa (RP).